The health ministry’s subcommittees decided at their joint meeting on December 25 to continue withholding an active recommendation for human papillomavirus (HPV) vaccines, maintaining the decision they made in October. Scientific evidence on two HPV vaccines approved in Japan, GlaxoSmithKline’s…
To read the full story
Related Article
- MHLW to Continue to Suspend HPV Vaccine Recommendation
September 18, 2015
REGULATORY
- MHLW Taps Kawabata to Lead Drug Discovery Support Office
April 15, 2026
- MHLW Reviewing EMIS Data on Petro-Product Supply to Medical Institutions
April 15, 2026
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
- LDP, Ishin to Explore Role of Private Insurance in Reform Talks
April 14, 2026
- Middle East War Hitting API Air Freight, Trade Group Warns
April 13, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





